M.S. in Biotechnology Management and Entrepreneurship Making the World Smarter, Safer and Healthier Request More Info Apply Now Attend an Info Session Contact Us Artificial Intelligence Biotechnology Computer Science Cybersecurity Data Analytics and Visualization Digital Marketing and Media Mathematics Occupational Therapy Physician Assistant Physics Speech-Language Pathology Eligible for STEM-OPT Affordable Fixed-Rate Tuition $30K After STEM Fellows Scholarship QS Rankings #63 University in the U.S. Alumni Career Outcomes 95% employed within 6 months M.S. in Biotechnology Management & Entrepreneurship 12 Courses I On-Campus in New York City I Full-Time or Part-Time The 36-credit M.S. in Biotechnology Management and Entrepreneurship is an interdisciplinary program designed specifically for the workforce needs of the biotechnology industry. This highly competitive program impacts society in the areas of food, fuel and health. In this program, you'll master the mission-critical scientific, technical and business knowledge needed to launch, manage, scale and commercialize biotechnology innovations and delivery systems. You’ll learn what it takes to shepherd a great idea through regulations, clinical trials, compliance and patents. And you'll merge your knowledge of science, technology and business, such as marketing, customer development, analytics and new business development, to effectively bring pharma and biotech products to market. From developing vaccines for infectious diseases, such as COVID-19, to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. And the industry is booming. Startups, large-multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with the M.S. in Biotechnology Management and Entrepreneurship. Program Highlights Master biotechnology foundations, including life sciences, biologics, biostatistics and clinical trials Gain business and entrepreneurship skills, such as new business development, marketing, finance for startups and business analytics Lead product, program and project management across the biotechnology ecosystem Career support and professional networking opportunities Gain industry experience through internships and research STEM-OPT eligible Full Program Breakdown M.S. in Biotechnology Management & Entrepreneurship 12 Courses I On-Campus in New York City I Full-Time or Part-Time The 36-credit M.S. in Biotechnology Management and Entrepreneurship is an interdisciplinary program designed specifically for the workforce needs of the biotechnology industry. This highly competitive program impacts society in the areas of food, fuel and health. In this program, you'll master the mission-critical scientific, technical and business knowledge needed to launch, manage, scale and commercialize biotechnology innovations and delivery systems. You’ll learn what it takes to shepherd a great idea through regulations, clinical trials, compliance and patents. And you'll merge your knowledge of science, technology and business, such as marketing, customer development, analytics and new business development, to effectively bring pharma and biotech products to market. From developing vaccines for infectious diseases, such as COVID-19, to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. And the industry is booming. Startups, large-multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with the M.S. in Biotechnology Management and Entrepreneurship. Program Highlights Master biotechnology foundations, including life sciences, biologics, biostatistics and clinical trials Gain business and entrepreneurship skills, such as new business development, marketing, finance for startups and business analytics Lead product, program and project management across the biotechnology ecosystem Career support and professional networking opportunities Gain industry experience through internships and research STEM-OPT eligible Swipe to learn more! M.S. in Biotechnology Management & Entrepreneurship 12 Courses I On-Campus in New York City I Full-Time or Part-Time The 36-credit M.S. in Biotechnology Management and Entrepreneurship is an interdisciplinary program designed specifically for the workforce needs of the biotechnology industry. This highly competitive program impacts society in the areas of food, fuel and health. In this program, you'll master the mission-critical scientific, technical and business knowledge needed to launch, manage, scale and commercialize biotechnology innovations and delivery systems. You’ll learn what it takes to shepherd a great idea through regulations, clinical trials, compliance and patents. And you'll merge your knowledge of science, technology and business, such as marketing, customer development, analytics and new business development, to effectively bring pharma and biotech products to market. From developing vaccines for infectious diseases, such as COVID-19, to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. And the industry is booming. Startups, large-multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with the M.S. in Biotechnology Management and Entrepreneurship. Master biotechnology foundations, including life sciences, biologics, biostatistics and clinical trials Gain business and entrepreneurship skills, such as new business development, marketing, finance for startups and business analytics Lead product, program and project management across the biotechnology ecosystem Career support and professional networking opportunities Gain industry experience through internships and research STEM-OPT eligible Research Design and conduct company-sponsored research on topics currently impacting the pharmaceutical and biotech industries or work alongside faculty in university labs. Current Projects Assessment of market size, competitive landscape and impact of Einstein-Montefiore Biotechnology Accelerated Research Center (EMBARC) — Company Sponsor: Albert Einstein College of Medicine Comprehensive startup market research to determine product market fit and investor profiles — Company Sponsor: BioVenture eLab at Weill Cornell Medicine Risk assessment and de-risking strategy for a new class of antibody drug conjugate for treatment of solid tumors — Company Sponsor: GritBio Etiology, treatment landscape, and patent search for A Gabapentin-Dextromethorphan-Quinidine combination product for treatment of chronic pain — Company Sponsor: BIOGVIR Commercialization plan for a novel toothpaste-based approach to treating peanut allergies — Company Sponsor: Introimmune Therapeutics Biotech Fellows Join students and alumni from over 30 countries to work on pioneering research, citywide initiatives and new technologies that help to make the world smarter, safer and healthier. Benefits Receive industry mentorship Showcase and publish your research at Katz School's annual Symposium on Science, Technology and Health Receive a generous tuition scholarship Learn more about the Fellows Program. B.A./M.S. Pathways Option Through the B.A./M.S. program, undergraduates from Yeshiva College and Stern College for Women can take up to nine graduate credits that count toward both the bachelor’s and master's degrees. After completing the bachelor’s, students can finish the graduate degree in just one more year. Admissions criteria: A minimum of 84 credits completed in any YC/SCW undergraduate major with a minimum GPA of 3.0 and a minimum grade of B in the prerequisite coursework listed below. Students can begin taking graduate courses in their senior year. For more information, visit www.yu.edu/pathways Internships and STEM-OPT Gain industry experience in major companies, startups and the YU Innovation Lab through internships that count toward your degree. The Master’s in Biotechnology Management and Entrepreneurship is a STEM-approved degree. International students may be eligible for up to 36 months of Optional Practical Training (OPT). The program also offers several opportunities for Curricular Practical Training (CPT). Recent Internships Merck Kantar Health BioMarin Marwood Group New York Stem Cell Foundation Lucerna SFA Therapeutics Interested in this program? Apply Now! Apply Now Program Links Curriculum Faculty Research Student Life Mission and Goals Learn More Admissions & Financial Aid Graduate Admissions katzgrad@yu.edu 646-592-4753 General Inquiries katz@yu.edu Join our Community LinkedIn Instagram YouTube Facebook Application Information Candidates must possess a bachelor's degree from an accredited college or university. Visit Graduate Admissions for up-to-date application requirements and deadlines. Questions? Schedule an appointment with an admissions director if you have questions about your qualifications, financial aid opportunities and financing your graduate degree. We can do a preliminary transcript review and discuss your admissions and financing options with the Katz School. Tuition, Financial Aid and Scholarships The Office of Student Finance maintains current tuition and fees for all graduate programs. All applicants are automatically considered for the STEM Fellows program. You do not need to submit any additional information. Learn More Graduate Admissions katzgrad@yu.edu 646-592-4753 General Inquiries katz@yu.edu Join our Community LinkedIn Instagram YouTube Facebook Admissions & Financial Aid Application Information Candidates must possess a bachelor's degree from an accredited college or university. Visit Graduate Admissions for up-to-date application requirements and deadlines. Questions? Schedule an appointment with an admissions director if you have questions about your qualifications, financial aid opportunities and financing your graduate degree. We can do a preliminary transcript review and discuss your admissions and financing options with the Katz School. Tuition, Financial Aid and Scholarships The Office of Student Finance maintains current tuition and fees for all graduate programs. All applicants are automatically considered for the STEM Fellows program. You do not need to submit any additional information. Program News Weill Cornell, Biotech Highlights Graduate Student Research Read about the research Weill Cornell, Biotech Highlights Graduate Student Research Collaborations, like the one between Weill Cornell Medicine and the Katz School’s M.S. in Biotechnology Management and Entrepreneurship, have emerged as catalysts for the development of the next generation of drugs, devices and services. Read the story in the Katz School blog. Less Dietary Sodium Key to Protecting Kidney Disease Patients Read about the paper's results Less Dietary Sodium Key to Protecting Kidney Disease Patients Managing an intricate balance between sodium intake, blood pressure and the volume of bodily fluid is key to minimizing the risk of further harm to individuals with end-stage kidney disease, according to a paper co-authored by Dr. Jochen Raimann, an industry professor in the M.S. in Biotechnology Management and Entrepreneurship.Read about the story in the Katz School blog. Alum's Kit Tests for Miscarriage Causes Read more about Rebecca's product idea Alum's Kit Tests for Miscarriage Causes Alumna Rebecca Russo-Schlossberg is developing an at-home miscarriage test kit for her own startup Genosa Diagnostics. More than half of miscarriages are the result of chromosomal abnormalities in the fertilized egg, which can cause developmental problems that result in an unviable fetus. Russo-Schlossberg’s test would be important because individuals who miscarry in their first trimester typically do so at home and thus don’t have the opportunity to genetically test the fetal tissue to determine a cause.Read the entire story here. Biotech Professor Writes Book on Innovation Read about what inspired Lorraine Marchand Biotech Professor Writes Book on Innovation In The Innovation Mindset, Lorraine Marchand shares her eight laws of innovation, a formula for driving significant and lasting transformation in any organization. Marchand emphasizes the frame of mind needed to spark the innovation process, underscoring the importance of creating a problem-solving culture and supporting personal curiosity, passion and talent.Read the entire story in the Katz blog. Students Targeting SUMO Proteins in Male Infertility Read about the YU-Katz Biotech research partnership Students Targeting SUMO Proteins in Male Infertility A Yeshiva University researcher and several Katz School graduate students will investigate how inhibiting the function of a cluster of small proteins in testicular cells affects spermatogenesis, or the production and regulation of sperm. The research is being supported in part by a grant from YU’s Provost Faculty Research Fund awarded to biotechnology Program Director Dr. Rana Kahn.Read entire story on the Katz blog. Sloan Kettering Hires Biotechnology Graduate Read more about Shanza Tariq's experience Sloan Kettering Hires Biotechnology Graduate When Shanza Baseer Tariq graduated in May with a master’s degree in biotechnology, she already had a publication track record and a job waiting for her as a research assistant at Memorial Sloan Kettering Cancer Center.Read the entire story in the Katz blog. Market Analysis Finds Commercial Promise for Cancer Drug Read more about the research Market Analysis Finds Commercial Promise for Cancer Drug Avi Strauss, a recent Katz School biotech graduate, has performed a detailed market analysis on a new drug therapy for colorectal cancer. The analysis recommended that Sapience Therapeutics, a New York-based biotech company, develop a molecule called a novel beta-catenin antagonist for treatment of the cancer. Beta-catenin is part of the Wnt signaling pathway, which promotes tumor growth and suppresses the immune system. In addition to colorectal cancer, Strauss reviewed four other types of cancer that have high mortality rates and resist conventional therapies: acute lymphocytic leukemia, breast cancer, melanoma, and multiple myeloma. He found that colorectal cancer patients would be a prime population for Sapience’s novel peptide because of the high incidence of a mutation in the Wnt signaling pathway that results in its overactivation and leads to the formation of cancer. “Colorectal cancer presents the highest upside according to the revenue projection model,” said Strauss, who is a healthcare consultant for the Marwood Group, “and presents the largest potential available population among the five cancer types studied.” Sapience’s therapeutic approach, according to Dr. Kappel, is to target protein-protein interactions (PPIs) that seem necessary to the survival of cancer or that inhibit the immune system’s response to cancerous tumors. The interactions targeted by Sapience are considered “undruggable” due to the intracellular location of the PPIs, making them difficult to treat with small-molecule drugs such as chemotherapies that are incapable of disrupting PPIs, and biologic-based drugs like monoclonal antibodies that are too big to enter cells. “Peptides combine the best properties of small and large molecules,” said Dr. Kappel, “and present an opportunity to disrupt intracellular PPIs and to reduce mortality in cancer patients and possibly in other diseases.” Robert Friedman, an adjunct professor in the biotechnology program and Strauss’s advisor, said that Strauss’s presentation demonstrates the strength of the “molecule-to-market nature” of the Katz School’s biotechnology program and its emphasis on understanding the science, and translating it into practical and actionable decisions. “Avi’s understanding of the science, clinical development and the market were all critical to successfully completing the project,” he said. “The piece de resistance of his elegant work is undoubtedly the market forecast model that the client will incorporate in its corporate planning process for years to come.” New York City a Hub for Biotech Innovation Read more about the city's $500 million investment New York City a Hub for Biotech Innovation Four of the top 10 biopharma clusters are located in the New York area. New York City’s Economic Development Corporation has started investing $500 million into LifeSciNYC, an initiative enshrining New York as a global leader in life sciences innovation and R&D. The initiative is also attracting entrepreneurs from around the world who have started 4,000 companies. From deploying therapeutic glycoproteins to treat autoimmune diseases to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. Startups, large multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with a master’s in biotechnology management and entrepreneurship. Weill Cornell, Biotech Highlights Graduate Student Research Read about the research Weill Cornell, Biotech Highlights Graduate Student Research Collaborations, like the one between Weill Cornell Medicine and the Katz School’s M.S. in Biotechnology Management and Entrepreneurship, have emerged as catalysts for the development of the next generation of drugs, devices and services. Read the story in the Katz School blog. Less Dietary Sodium Key to Protecting Kidney Disease Patients Read about the paper's results Less Dietary Sodium Key to Protecting Kidney Disease Patients Managing an intricate balance between sodium intake, blood pressure and the volume of bodily fluid is key to minimizing the risk of further harm to individuals with end-stage kidney disease, according to a paper co-authored by Dr. Jochen Raimann, an industry professor in the M.S. in Biotechnology Management and Entrepreneurship.Read about the story in the Katz School blog. Alum's Kit Tests for Miscarriage Causes Read more about Rebecca's product idea Alum's Kit Tests for Miscarriage Causes Alumna Rebecca Russo-Schlossberg is developing an at-home miscarriage test kit for her own startup Genosa Diagnostics. More than half of miscarriages are the result of chromosomal abnormalities in the fertilized egg, which can cause developmental problems that result in an unviable fetus. Russo-Schlossberg’s test would be important because individuals who miscarry in their first trimester typically do so at home and thus don’t have the opportunity to genetically test the fetal tissue to determine a cause.Read the entire story here. Biotech Professor Writes Book on Innovation Read about what inspired Lorraine Marchand Biotech Professor Writes Book on Innovation In The Innovation Mindset, Lorraine Marchand shares her eight laws of innovation, a formula for driving significant and lasting transformation in any organization. Marchand emphasizes the frame of mind needed to spark the innovation process, underscoring the importance of creating a problem-solving culture and supporting personal curiosity, passion and talent.Read the entire story in the Katz blog. Students Targeting SUMO Proteins in Male Infertility Read about the YU-Katz Biotech research partnership Students Targeting SUMO Proteins in Male Infertility A Yeshiva University researcher and several Katz School graduate students will investigate how inhibiting the function of a cluster of small proteins in testicular cells affects spermatogenesis, or the production and regulation of sperm. The research is being supported in part by a grant from YU’s Provost Faculty Research Fund awarded to biotechnology Program Director Dr. Rana Kahn.Read entire story on the Katz blog. Sloan Kettering Hires Biotechnology Graduate Read more about Shanza Tariq's experience Sloan Kettering Hires Biotechnology Graduate When Shanza Baseer Tariq graduated in May with a master’s degree in biotechnology, she already had a publication track record and a job waiting for her as a research assistant at Memorial Sloan Kettering Cancer Center.Read the entire story in the Katz blog. Market Analysis Finds Commercial Promise for Cancer Drug Read more about the research Market Analysis Finds Commercial Promise for Cancer Drug Avi Strauss, a recent Katz School biotech graduate, has performed a detailed market analysis on a new drug therapy for colorectal cancer. The analysis recommended that Sapience Therapeutics, a New York-based biotech company, develop a molecule called a novel beta-catenin antagonist for treatment of the cancer. Beta-catenin is part of the Wnt signaling pathway, which promotes tumor growth and suppresses the immune system. In addition to colorectal cancer, Strauss reviewed four other types of cancer that have high mortality rates and resist conventional therapies: acute lymphocytic leukemia, breast cancer, melanoma, and multiple myeloma. He found that colorectal cancer patients would be a prime population for Sapience’s novel peptide because of the high incidence of a mutation in the Wnt signaling pathway that results in its overactivation and leads to the formation of cancer. “Colorectal cancer presents the highest upside according to the revenue projection model,” said Strauss, who is a healthcare consultant for the Marwood Group, “and presents the largest potential available population among the five cancer types studied.” Sapience’s therapeutic approach, according to Dr. Kappel, is to target protein-protein interactions (PPIs) that seem necessary to the survival of cancer or that inhibit the immune system’s response to cancerous tumors. The interactions targeted by Sapience are considered “undruggable” due to the intracellular location of the PPIs, making them difficult to treat with small-molecule drugs such as chemotherapies that are incapable of disrupting PPIs, and biologic-based drugs like monoclonal antibodies that are too big to enter cells. “Peptides combine the best properties of small and large molecules,” said Dr. Kappel, “and present an opportunity to disrupt intracellular PPIs and to reduce mortality in cancer patients and possibly in other diseases.” Robert Friedman, an adjunct professor in the biotechnology program and Strauss’s advisor, said that Strauss’s presentation demonstrates the strength of the “molecule-to-market nature” of the Katz School’s biotechnology program and its emphasis on understanding the science, and translating it into practical and actionable decisions. “Avi’s understanding of the science, clinical development and the market were all critical to successfully completing the project,” he said. “The piece de resistance of his elegant work is undoubtedly the market forecast model that the client will incorporate in its corporate planning process for years to come.” New York City a Hub for Biotech Innovation Read more about the city's $500 million investment New York City a Hub for Biotech Innovation Four of the top 10 biopharma clusters are located in the New York area. New York City’s Economic Development Corporation has started investing $500 million into LifeSciNYC, an initiative enshrining New York as a global leader in life sciences innovation and R&D. The initiative is also attracting entrepreneurs from around the world who have started 4,000 companies. From deploying therapeutic glycoproteins to treat autoimmune diseases to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. Startups, large multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with a master’s in biotechnology management and entrepreneurship.